Caris Life Sciences vs Castle Biosciences
CAI and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and CSTL compare
Caris Life Sciences is the larger company, worth 8.5 times as much as Castle Biosciences ($9.7B against $1.1B).
Caris Life Sciences grew revenue faster over the last twelve months (85.4% versus 3.2% for Castle Biosciences).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 10.6% compared with −5.4% at Castle Biosciences.
Castle Biosciences scores higher on the StockData Score (10 against 8 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | $9.7B | $1.1B |
| Share price | $34.33 | $37.16 |
| Change, 1 year | 16.6% | 56.5% |
| Change, 5 years | – | −37.6% |
| Beta (5Y) | 2.10 | 1.38 |
| Employees | 1,846 | 883 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 3 | 3 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.8× | 3.2× (better) |
| P/B | 16.4× | 2.4× (better) |
| EV/EBITDA | 57.4× | – |
| P/FCF | 78.3× | – |
| FCF yield | 1.3% (better) | −0.04% |
| Fair value | $14.85 | $36.59 |
| Margin of safety | −131% | −1.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 85.4% (better) | 3.2% |
| Revenue growth, 5Y average | – | 40.6% |
| Profitability | ||
| Gross margin | – | 77.3% |
| Operating margin | 15.5% (better) | −9.0% |
| Net margin | 10.6% (better) | −5.4% |
| FCF margin | 12.5% (better) | −0.14% |
| Return on equity | 20.1% (better) | −4.2% |
| Return on invested capital | 31.0% (better) | −12.6% |
| Financial health | ||
| Debt / equity | 0.66 | 0.02 (better) |
| Net debt / EBITDA | 1.67 | – |
| Interest coverage | 3.3× (better) | −85.6× |
| Current ratio | 5.53 | 6.04 (better) |
| Altman Z-score | 8.28 (better) | 7.93 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | 0.22% | – |
| Shareholder yield | 0.22% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 89.5% |
| Held by insiders | 64.1% | 2.0% |
| Insider net buying, 12 months | −$27.3M | −$17.7M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 13.7% | 6.7% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.